Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Open access
Armitage, Jane, Baigent, Colin, Barnes, Elizabeth, Betteridge, D John, Blackwell, Lisa, Blazing, Michael, Bowman, Louise, Braunwald, Eugene, Byington, Robert, Cannon, Christopher, Clearfield, Michael, Colhoun, Helen, Collins, Rory, Dahlöf, Björn, Davies, Kelly, Davis, Barry, de Lemos, James, Downs, John R, Durrington, Paul, Emberson, Jonathan, Fellström, Bengt, Flather, Marcus, Ford, Ian, Franzosi, Maria Grazia, Fulcher, Jordan, Fuller, John, Furberg, Curt, Gordon, David, Goto, Shinya, Gotto, Antonio, Halls, Heather, Harper, Charlie, Hawkins, C Morton, Herrington, Will, Hitman, Graham, Holdaas, Hallvard, Holland, Lisa, Jardine, Alan, Jukema, J Wouter, Kastelein, John, Kean, Sharon, Keech, Anthony, Kirby, Adrienne, Kjekshus, John, Knatterud (deceased), Genell, Knopp (deceased), Robert, Koenig, Wolfgang, Koren, Michael, Krane, Vera, Landray, Martin J, LaRosa, John, Lonn, Eva, MacFarlane, Peter, MacMahon, Stephen, Maggioni, Aldo, Marchioli, Roberto, Marschner, Ian, Mihaylova, Borislava, Moyé, Lemuel, Murphy, Sabina, Nakamura, Haruo, Neil, Andrew, Newman, Connie, O'Connell, Rachel, Packard, Chris, Parish, Sarah, Pedersen, Terje, Peto, Richard, Pfeffer, Marc, Poulter, Neil, Preiss, David, Reith, Christina, Ridker, Paul, Robertson, Michele, Sacks, Frank, Sattar, Naveed, Schmieder, Roland, Serruys, Patrick, Sever, Peter, Shaw, John, Shear, Charles, Simes, John, Sleight, Peter, Spata, Enti, Tavazzi, Luigi, Tobert, Jonathan, Tognoni, Gianni, Tonkin, Andrew, Trompet, Stella, Varigos, John, Wanner, Christoph, Wedel, Hans, White, Harvey, Wikstrand, John, Wilhelmsen, Lars, Wilson, Kate, Young, Robin, Yusuf, Salim, Zannad, Faiez · 2019 · The Lancet

Abstract

Background Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages. Methods In this meta-analysis, randomised trials of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). We subdivided participants into six age groups (55 years or younger, 56–60 years, 61–65 years, 66–70 years, 71–75 years, and older than 75 years). We estimated effects on major vascular events (ie, major coronary events, strokes, and coronary revascularisations), cause-specific mortality, and cancer incidence as the rate ratio (RR) per 1·0 mmol/L reduction in LDL cholesterol. We compared proportional risk reductions in different age subgroups by use of standard χ 2 tests for heterogeneity when there were two groups, or trend when there were more than two groups. Findings 14 483 (8%) of 186 854 participants in the 28 trials were older than 75 years at randomisation, and the median follow-up duration was 4·9 years. Overall, statin therapy or a more intensive statin regimen produced a 21% (RR 0·79, 95% CI 0·77–0·81) proportional reduction in major vascular events per 1·0 mmol/L reduction in LDL cholesterol. We observed a significant reduction in major vascular events in all age groups. Although proportional reductions in major vascular events diminished slightly with age, this trend was not statistically significant (p trend =0·06). Overall, statin or more intensive therapy yielded a 24% (RR 0·76, 95% CI 0·73–0·79) proportional reduction in major coronary events per 1·0 mmol/L reduction in LDL cholesterol, and with increasing age, we observed a trend towards smaller proportional risk reductions in major coronary events (p trend =0·009). We observed a 25% (RR 0·75, 95% CI 0·73–0·78) proportional reduction in the risk of coronary revascularisation procedures with statin therapy or a more intensive statin regimen per 1·0 mmol/L lower LDL cholesterol, which did not differ significantly across age groups (p trend =0·6). Similarly, the proportional reductions in stroke of any type (RR 0·84, 95% CI 0·80–0·89) did not differ significantly across age groups (p trend =0·7). After exclusion of four trials which enrolled only patients with heart failure or undergoing renal dialysis (among whom statin therapy has not been shown to be effective), the trend to smaller proportional risk reductions with increasing age persisted for major coronary events (p trend =0·01), and remained non-significant for major vascular events (p trend =0·3). The proportional reduction in major vascular events was similar, irrespective of age, among patients with pre-existing vascular disease (p trend =0·2), but appeared smaller among older than among younger individuals not known to have vascular disease (p trend =0·05). We found a 12% (RR 0·88, 95% CI 0·85–0·91) proportional reduction in vascular mortality per 1·0 mmol/L reduction in LDL cholesterol, with a trend towards smaller proportional reductions with older age (p trend =0·004), but this trend did not persist after exclusion of the heart failure or dialysis trials (p trend =0·2). Statin therapy had no effect at any age on non-vascular mortality, cancer death, or cancer incidence. Interpretation Statin therapy produces significant reductions in major vascular events irrespective of age, but there is less direct evidence of benefit among patients older than 75 years who do not already have evidence of occlusive vascular disease. This limitation is now being addressed by further trials. Funding Australian National Health and Medical Research Council, National Institute for Health Research Oxford Biomedical Research Centre, UK Medical Research Council, and British Heart Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31942-1

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects on major vascular events per mmol/L reduction in LDL cholesterol by age at randomisation All studies (A) and excluding four trials that exclusively included patients with heart failure or on dialysis (B). Data from participants with missing baseline data included in the totals. RR=rate ratio.
Figure 1 Effects on major vascular events per mmol/L reduction in LDL cholesterol by age at randomisation All studies (A) and excluding four trials that exclusively included patients with heart failure or on dialysis (B). Data from participants with missing baseline data included in the totals. RR=rate ratio.CC BY-NC-ND · PubMed Central
Figure 2 Effects on major vascular events per mmol/L reduction in LDL cholesterol, subdivided by age at randomisation and particular trial populations Data from participants with missing baseline data included in the totals. RR=rate ratio.
Figure 2 Effects on major vascular events per mmol/L reduction in LDL cholesterol, subdivided by age at randomisation and particular trial populations Data from participants with missing baseline data included in the totals. RR=rate ratio.CC BY-NC-ND · PubMed Central
Figure 3 Effects on components of major vascular events per mmol/L reduction in LDL cholesterol in all studies, by age at randomisation Data from participants with missing baseline data included in the totals. RR=rate ratio.
Figure 3 Effects on components of major vascular events per mmol/L reduction in LDL cholesterol in all studies, by age at randomisation Data from participants with missing baseline data included in the totals. RR=rate ratio.CC BY-NC-ND · PubMed Central
Figure 4 Effects on major vascular events per mmol/L reduction in LDL cholesterol, subdivided by age at randomisation and by previous vascular disease Data from participants with missing baseline data included in the totals. RR=rate ratio.
Figure 4 Effects on major vascular events per mmol/L reduction in LDL cholesterol, subdivided by age at randomisation and by previous vascular disease Data from participants with missing baseline data included in the totals. RR=rate ratio.CC BY-NC-ND · PubMed Central
Figure 5 Effects on vascular death per mmol/L reduction in LDL cholesterol, subdivided by age at randomisation All studies (A) and excluding four trials that exclusively included patients with heart failure or on dialysis (B). Data from participants with missing baseline data included in the totals. RR=rate ratio.
Figure 5 Effects on vascular death per mmol/L reduction in LDL cholesterol, subdivided by age at randomisation All studies (A) and excluding four trials that exclusively included patients with heart failure or on dialysis (B). Data from participants with missing baseline data included in the totals. RR=rate ratio.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 46 references

Research works printed but not linked: 1

  1. 2013, KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease, Kidney Int Suppl, 3, 259

Cited by

See all 920

Metadata

Authors
Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., Clearfield, M., Colhoun, H., Collins, R., Dahlöf, B., Davies, K., Davis, B., de Lemos, J., Downs, J. R., Durrington, P., Emberson, J., Fellström, B., Flather, M., Ford, I., Franzosi, M. G., Fulcher, J., Fuller, J., Furberg, C., Gordon, D., Goto, S., Gotto, A., Halls, H., Harper, C., Hawkins, C. M., Herrington, W., Hitman, G., Holdaas, H., Holland, L., Jardine, A., Jukema, J. W., Kastelein, J., Kean, S., Keech, A., Kirby, A., Kjekshus, J., Knatterud (deceased), G., Knopp (deceased), R., Koenig, W., Koren, M., Krane, V., Landray, M. J., LaRosa, J., Lonn, E., MacFarlane, P., MacMahon, S., Maggioni, A., Marchioli, R., Marschner, I., Mihaylova, B., Moyé, L., Murphy, S., Nakamura, H., Neil, A., Newman, C., O'Connell, R., Packard, C., Parish, S., Pedersen, T., Peto, R., Pfeffer, M., Poulter, N., Preiss, D., Reith, C., Ridker, P., Robertson, M., Sacks, F., Sattar, N., Schmieder, R., Serruys, P., Sever, P., Shaw, J., Shear, C., Simes, J., Sleight, P., Spata, E., Tavazzi, L., Tobert, J., Tognoni, G., Tonkin, A., Trompet, S., Varigos, J., Wanner, C., Wedel, H., White, H., Wikstrand, J., Wilhelmsen, L., Wilson, K., Young, R., Yusuf, S., & Zannad, F.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-02
Volume
393
Issue
10170
Pages
407-415
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2914546434
Cited by
801
References
46
Citations by year
2026: 67 · 2025: 83 · 2024: 108 · 2023: 111 · 2022: 92 · 2021: 122 · 2020: 128 · 2019: 87
FWCI
22.11
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by-nc-nd)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by-nc-nd)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc-nd)
Funders
  • National Heart Foundation of Australia
  • British Heart Foundation
  • Cancer Research UK
  • NIHR Bristol Biomedical Research Centre
  • Medical Research Council
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords
statin therapy, older adults, age differences in treatment response, major vascular events, coronary events, stroke, coronary revascularization, vascular death, cancer incidence, LDL cholesterol lowering, high-intensity statin therapy, statin safety, cardiovascular risk reduction
MeSH terms
Age Factors, Aged, Humans, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31942-1
The paper
Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., Clearfield, M., Colhoun, H., Collins, R., Dahlöf, B., Davies, K., Davis, B., de Lemos, J., Downs, J. R., Durrington, P., . . . Zannad, F. (2019). Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet. https://doi.org/10.1016/s0140-6736(18)31942-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.